Guangji Pharmaceutical price increases will be released downstream demand ribofl
Guangji Pharmaceutical riboflavin on the main product price increases of about 1 percent, which may be seen as two days ago of BASF's response to price increases. Back in 2007, price increases have created a wide riboflavin economic medicine super Ushimata image, now, more than half of the two monopoly companies have global price increase of riboflavin, or indicates that the industry will accelerate into the warmer VB2 track .
Guangji Pharmaceutical today announced, as raw material prices, according to market conditions, the company decided on the main product?? 80% of feed-grade riboflavin (VB2) products offer up 8-12%.
According to announcement, 80% feed grade riboflavin riboflavin products accounted for the total company for about 65% of its 2009 annual sales of approximately for 40% of company revenue.
Same time, the announcement also said that improving riboflavin product of this offer, market acceptability and price of the price increase can not determine how long, now we can not predict its impact.
Is worth noting that on May 10, BASF issued notice on its official website, saying that now on a global scale will be food grade and feed grade VB2 prices increased by 10%, the main reason for price increase raw materials prices push.
The first price increase in the broad economic front of the world's second oldest profession BASF Department of riboflavin. To the situation of 2009, industry, global production capacity of 80% of riboflavin concentration of medicine in the broad economy, BASF, DSM and three corporations. Among the largest is the broad economic output medicine, the existing production capacity of 2,300 tons, in addition to Henan Mengzhou still under construction in 2500 tons of production capacity is gradually released. BASF plant in Korea is smaller than Guangji Pharmaceutical, DSM riboflavin production of its major suppliers of multi-dimensional self feed, so outside of riboflavin for basic market for the broad economic medicine and BASF occupied.
A result, BASF, wide price increase in real terms has been the economic equivalent of the global VB2 overall price increase, which indicates that the industry or from a cyclical peak in 2007, after the financial crisis, 2008,2009, after falling to the bottom , re-entered the recovery track.
Search VB2 Industry Association data, VB2 (80%) 9,10 months from the beginning of 2006 prices, up to 7-8 months in 2007 reached a historic peak 900 yuan / kg, then the price way down, in 2008 prices prices have fallen to the level before the first half of 2009 prices continue falling, but in the second half improved, from the lowest point of 110 yuan / kg up to the present 140 yuan / kg.
Contrast, the operating results of extensive economic, the company achieved sales revenue in 2009 448 million, down 21.61 percent; a net profit of 43 million yuan, down 51.73 percent; after deducting non-recurring gains and losses net profit 22.8 million, down 73.6% year on year .
Can see, the financial crisis will not only allow riboflavin prices hovering in the valley bottom periodically, but also to make such broad economic medicine manufacturers in the small profit edges. Back to investigate earnings, profit margins from 60% in 2007 plunged 21.4% in 2009. Now, BASF and the economy have wide price increases, though his mind is still cost-push (as VB2 materials?? Heilongjiang corn spot prices from 2009 to 1400 yuan / ton rose to the current 1,750 yuan / ton), but still release confidence in the downstream demand and gradually pick up the signal VB2 industry.
I am an expert from disposablemedicalsuppliers.com, while we provides the quality product, such as Yoga Netipot , Disposable Vaginal Speculum, disposable medical exporter,and more.
Processing your request, Please wait....
